Eli Lilly and Company (LLY)
Receivables turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 34,124,100 | 28,541,400 | 28,318,400 | 24,539,800 | 22,319,500 |
Receivables | US$ in thousands | 11,336,200 | 6,896,000 | 6,672,800 | 5,875,300 | 4,547,300 |
Receivables turnover | 3.01 | 4.14 | 4.24 | 4.18 | 4.91 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $34,124,100K ÷ $11,336,200K
= 3.01
Lilly(Eli) & Co's receivables turnover has exhibited a gradual decline over the past five years, decreasing from 4.03 in 2019 to 3.01 in 2023. This indicates that the company is taking longer to collect payments from its customers. A lower receivables turnover ratio may suggest a potential issue with the company's credit policy, collection practices, or the quality of its customers. It is essential for Lilly(Eli) & Co to closely monitor and improve its accounts receivable management to ensure timely collections and optimize its working capital efficiency.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
Eli Lilly and Company
LLY
3.01
Abbott Laboratories
ABT
6.01
AbbVie Inc
ABBV
4.87
Alkermes Plc
ALKS
4.93
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.75
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44